EXHIBIT 99.2

FOR IMMEDIATE RELEASE

Investor Contacts:
Richard T. Schumacher, President & CEO                Pressure BioSciences, Inc.
Edward H. Myles, VP of Finance and CFO                        (508) 580-1818 (T)


                   PRESSURE BIOSCIENCES, INC. PLACES ORDER FOR
            25 BENCH TOP BAROCYCLER UNITS FROM SOURCE SCIENTIFIC, LLC

West Bridgewater, MA, April 5, 2006 - Pressure BioSciences, Inc. (NASDAQ: PBIO)
today announced it has placed an order for 25 Barocycler NEP3229 units with
Source Scientific, LLC, the manufacturer of the Company's PCT equipment and
disposable products line. The NEP3229 is the new bench top version of the
Company's pressure cycling instrument (the Barocyler), designed to be a more
cost-effective and user-friendly alternative to the original floor model
Barocycler instrument, the NEP2017. Sixteen NEP3229 units were initially
manufactured between June and December of 2005 as part of the Company's
strategic plan to have the instruments evaluated in leading laboratories
throughout North America and Japan. Of these sixteen units, five have been sold,
six are in the laboratories of collaborators, three will soon be shipped to new
collaborator sites, and two are being used for internal R&D.

Richard T. Schumacher, Founder, President, and CEO of PBI said: "The safe,
efficient, and reproducible extraction of DNA, RNA, proteins, and small
molecules from cell and tissue samples is essential to the tens of thousands of
investigators working in genomic and proteomic research today. This is true
regardless whether the researcher is working with human, animal, plant, or
microbial materials. To that end, we believe that the PCT Sample Preparation
System (PCT SPS) offers many clear and important advantages over all other
extraction methods currently available, especially for those samples generally
considered "hard-to-lyse" (i.e., hard to open). Over the past year, we have been
working diligently with collaborators to help generate the data necessary to
highlight these advantages. We are therefore very pleased that investigators
from several nationally-recognized laboratories have recently given
presentations at scientific meetings that underscore the advantages of the PCT
SPS."

Mr. Schumacher continued: "Because of this increased interest in the PCT SPS, we
placed an order with Source Scientific for 25 Barocycler NEP3229 units to be
delivered over the course of 2006. These new, bench top instruments will give us
the opportunity to work with thought leaders and experts in new and important
areas of the life sciences, as well as to have a significant number of
instruments readily available for sale."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company
focused on the development of a novel technology called Pressure Cycling
Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and
ultra-high levels (up to 35,000 psi and greater) to control bio-molecular

                                       10

interactions. PBI currently holds 13 US and 4 foreign patents covering multiple
applications of PCT in the life sciences field, including in such areas as
genomic and proteomic sample preparation, pathogen inactivation, the control of
enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions,
hopes, beliefs, expectations or predictions of the future are "forward-looking''
statements within the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the magnitude of the need by
investigators to extract DNA, RNA, proteins, and small molecules from cell and
tissue samples, the Company's expectations about the market interest in the PCT
SPS, the purchase of the 25 additional NEP3229 units, the Company's expectations
about the addition of new collaboration sites, and the potential for the sale of
some or all of the additional 25 instruments. These statements are based upon
the Company's current expectations, forecasts, and assumptions that are subject
to risks, uncertainties, and other factors that could cause actual outcomes and
results to differ materially from those indicated by these forward-looking
statements. These risks, uncertainties, and other factors include, but are not
limited to: fluctuations in the Company's financial and operating results that
could adversely affect the Company's cash flow; uncertainties inherent in the
development of the PCT SPS, including technical risks, cost overruns, and
manufacturing and other delays; the risk that the market will not recognize the
advantages of the PCT SPS over other currently available extraction methods; the
risk that the Company will not be able to increase demand or sales for its
products; and the other risks and uncertainties discussed under the heading
"Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended
December 31, 2005 and other reports filed by the Company from time to time with
the SEC. The Company undertakes no obligation to update any of the information
included in this release, except as otherwise required by law.


           Visit us at our website http://www.pressurebiosciences.com

                                       11